Bulletin
Investor Alert

Market Pulse Archives

Sept. 18, 2020, 6:27 a.m. EDT

Athira Pharma prices upsized IPO at $17, high end of price range

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Athira Pharma Inc. (ATHA)

or Cancel Already have a watchlist? Log In

By Ciara Linnane

ATHA

Athira Pharma Inc. /zigman2/quotes/221121520/composite ATHA +1.24% priced its initial public offering at $17 a share, the top end of its proposed price range. The company upsized the deal to 12 million shares from an original plan to offer 10 million shares, to raise $204 million. The stock will start trading on Nasdaq later Friday, under the ticker "ATHA." Goldman Sachs, Jefferies and Stifel were lead book runners on the deal with JMP Securities acting as co-manager. Proceeds will be used to finance clinical trials. "We are a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration," the company says in its IPO prospectus.

/zigman2/quotes/221121520/composite
US : U.S.: Nasdaq
$ 18.76
+0.23 +1.24%
Volume: 259,074
Oct. 27, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$571.08 million
Rev. per Employee
N/A
loading...

Get news alerts on Athira Pharma Inc. — or create your own.
This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.